

COPY

PTO/SB/08 (2-92)

Sheet 1 of 3

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 252312007400

Application Number 09/724,822

Applicant

Matthew D. LINNIK and Patricia A. McNEELY

Filing Date November 28, 2000

Group Art Unit 1646

Mailing Date September 18, 2001

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
CA	1.	11/10/1992	5,162,515	Conrad et al.			
	2.	12/07/1993	5,268,454	Barstad et al.			
	3.	01/04/1994	5,276,013	Conrad et al.			
	4.	12/06/1994	5,370,871	Dintzis et al.			
	5.	02/21/1995	5,391,785	Jones et al.			
	6.	09/03/1996	5,552,391	Coutts et al.			
	7.	02/25/1997	5,606,047	Coutts et al.			
	8.	05/27/1997	5,633,395	Coutts et al.			
	9.	03/10/1998	5,726,329	Jones et al.			
	10.	07/28/1998	5,786,512	Jones et al.			
	11.	02/23/1999	5,874,409	Victoria et al.			
	12.	02/08/2000	6,022,544	Dintzis et al.			
	13.	05/09/2000	6,060,056	Coutts et al.			
✓	14.	03/27/2001	6,207,160 B1	Victoria et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
CA	15.	12/19/1996	WO 96/40197	PCT			
	16.	12/11/1997	WO 97/46251	PCT			
	17.	12/16/1999	WO 99/64595	PCT			
	18.	06/15/2000	WO 00/33887	PCT			
	19.	06/15/2000	WO 00/34231	PCT			
	20.	06/15/2000	WO 00/34296	PCT			
✓	21.	12/14/2000	WO 00/75105	PCT			

EXAMINER:

DATE CONSIDERED:


8/7/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/08 (2-92)
Sheet 2 of 3

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 252312007400	Application Number 09/724,822
		Applicant Matthew D. LINNIK and Patricia A. McNEELY	
		Filing Date November 28, 2000	Group Art Unit 1646
		Mailing Date September 18, 2001	
OTHER DOCUMENTS <i>(including author, title, Date, Pertinent Pages, Etc.)</i>			
Examiner Initials	Ref. No.	Title	
CQ	20.	Bootsma, H. et al. (1995). "Prevention of Relapses in Systematic Lupus Erythematosus", <i>Lancet</i> , 345:1595-1599.	
	21.	Borel, Y. et al. (1990) "A Novel Technique to Link Either Proteins or Peptides to Gammaglobulin to Construct Tolerogens" <i>J. Immunol. Methods</i> 126:159-168.	
	22.	Borel, Y. et al. (1995) "Food Allergens Transformed into Tolerogens" <i>Int. Arch. Allergy Immunol.</i> 107:264-267.	
	23.	Borel, Y. et al. (1996) "Parenteral and Oral Administration of Tolerogens: Protein-IgG Conjugates" <i>Ann. N.Y. Acad. Sci.</i> 778:80-87.	
	24.	Borg, E. J. et al. (1990). "Measurement of Increases in Anti-Double-Stranded DNA Antibody Levels as a Predictor of Disease Exacerbation in Systemic Lupus Erythematosus", <i>Arthritis Rheumatism</i> . 33:634-643.	
	25.	Coutts, S. M. et al. (1996). "Pharmacological Intervention in Antibody Mediated Disease", <i>Lupus</i> 5:158-159.	
	26.	Dintzis, R. Z. et al. (1983). "Studies on the Immunogenicity and Tolerogenicity of T-Independent Antigens", <i>The Journal of Immunology</i> 13(5):2196-2203.	
	27.	Dintzis, R. Z. et al. (1989). "The Immunogenicity of Soluble Haptenated Polymers is Determined by Molecular Mass and Hapten Valence", <i>The Journal of Immunology</i> 143:1239-1244.	
	28.	Dumas, V. et al. (1995). "Induction of Tolerance by Administration of Hapten-Immunoglobulin Conjugates is Associated with Decreased IL-2 and IL-4 Production", <i>Arch. Dermatol. Res.</i> , 287:123-128.	
	29.	Foster, M. H. et al. (1993). "Biology of Disease Nephritogenic Autoantibodies in Systematic Lupus Erythematosus: Immunochemical Properties, Mechanisms of Immune Deposition, and Genetic Origins", <i>Laboratory Investigation</i> , 69(5):494-507.	
	30.	Jones, D. et al. (1994). "Conjugates of Double-Stranded Oligonucleotides with Poly(ethylene glycol) and Keyhole Limpet Hemocyanin: a Model for Treating Systematic Lupus Erythematosus", <i>Bioconjugate Chemistry</i> 5:390-399.	
	31.	Jones, D. et al. (1995). "Immunospecific Reduction of Antioligonucleotide Antibody-Forming Cells with a Tetraakis-Oligonucleotide Conjugate (LJP 394), a Therapeutic Candidate for the Treatment of Lupus Nephritis", <i>J. Med. Chem.</i> 38:2138-2144.	
32.	Morimoto, C. et al. (1982). "A Defect of Immunoregulatory T Cell Subsets in Systematic Lupus Erythematosus Patients Demonstrated with Anti-2H4 Antibody", <i>The Journal of Immunology</i> 139:1960-1965.		
EXAMINER: 		DATE CONSIDERED: 8/17/03	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE			

PTO/SB/ 08 (2-92)

PTO/SB/08 (2-92)
Sheet 3 of 3

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312007400	Application Number 09/724,822
	Applicant Matthew D. LINNIK and Patricia A. McNEELY	
	Filing Date November 28, 2000	Group Art Unit 1646
	Mailing Date September 18, 2001	

CQ	33.	Plunkett, M. L. et al. (1995). "LJP 394: A Novel Clinical Candidate for the Treatment of Lupus Nephritis", <i>Lupus</i> 4:S99.
	34.	Seleznick, M. J. et al. (1991). "Variables Associated with Decreased Survival in Systematic Lupus Erythematosus", <i>Seminars in Arthritis and Rheumatism</i> 21:73-80.
	35.	Sem, D. S. et al. (1999). "Antibody Affinities and Relative Titers in Polyclonal Population: Surface Plasmon Resonance Analysis of Anti-DNA Antibodies", <i>Archives of Biochemistry and Biophysics</i> 1:372(1):62-68.
	36.	Weisman, M. H. et al. (1997). "Reduction in Circulating dsDNA Antibody Titer after Administration of LJP 394", <i>The Journal of Rheumatology</i> 24:314-318.

EXAMINER:

DATE CONSIDERED:

8/7/03


EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/08 (2-92)
Sheet 1 of 1

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312007400	Application Number 09/724,822
	Applicant Matthew D. LINNIK and Patricia A. McNEELY	
	Filing Date: November 28, 2000	Group Art Unit 1646
	Mailing Date: November 7, 2001	



U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
CR	1.	07/24/1991	EP 0 438 259 A1	Europe			
CR	2.	03/15/1995	EP 0 642 798 A2	Europe			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
CR	3.	Aharoni, A. et al., (1993) "Characterization of a multisubunit human protein which selectively binds single stranded d(GA) _n and d(GT) _n sequence repeats in DNA" <i>Nucl. Acid. Res.</i> 21(22):5221-5228.

RECEIVED
DEC 20 2001
TECH CENTER 1600/2900

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)
pa-640827

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

COPY OF PAPERS
ORIGINALLY FILED

PTO/SB/08 (2-92)

Sheet 1 of 1

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 252312007400

Application Number 09/724,822

Applicant

Matthew D. LNNIK and Patricia A. MCNEELEY

Filing Date November 28, 2000

Group Art Unit 1633

Mailing Date February 27, 2002

RECEIVED

MAR 14 2002

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
CA	1.	McNeeley, P.A. (2001). "Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients," <i>Lupus</i> 10:526-532.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2-92)
pa-670019

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE



PTO/SB/08 (2-92)

Sheet 1 of 1

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number 252312007400	Application Number 09/724,822
	Applicant Matthew D. LINNIK and Patricia A. MCNEELEY	
	Filing Date November 28, 2000	Group Art Unit 1636
	Mailing Date September 13, 2002	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
CR	1.	03/26/2002	6,362,254 B2	Harris et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
CR	2.	08/12/1999	WO 99/40434 A1	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
CR	3.	Jones, D. et al. (May-June 1999). "Multivalent thioether-peptide conjugates: B cell tolerance of an anti-peptide immune response" <i>Bioconjugate Chemistry</i> 10(3):480-488.
↓	4.	Jones, D. et al. (2000). "A Convenient Synthesis of N-(tert-butyloxycarbonyl) Aminoxy Ethers," <i>Tetrahedron Letters</i> 41: 1531-1533.
↓	5.	La Jolla Pharmaceutical Company Publication (January 11, 2001) "La Jolla Pharmaceutical announces that in three clinical trials 90% of lupus patients have key antibodies", findings presented at JP Morgan H & Q Healthcare Conference, San Francisco, 3 pages.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2-92)

DA-704423

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

H/8

PTO/SB/08 (2-92)

Sheet 1 of 2

Form PTO-849

Docket Number 252312007400

Application Number 09/724,822

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Matthew D. LINNIK and Patricia A. McNEELEY

Filing Date November 28, 2000

Group Art Unit 1636

Mailing Date April 17, 2003

COPY

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
CR	1.	06/30/1992	5,126,131	Dintzis et al.			
	2.	11/28/1995	5,470,570	Taylor et al.			
	3.	01/30/1996	5,487,890	Taylor et al.			
	4.	03/09/1999	5,879,679	Taylor et al.			
	5.	06/04/2002	6,399,578	Jack et al.			
	6.	10/01/2002	6,458,953	Jones			

RECEIVED

APR 23 2003

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
CR	7.	08/20/1992	WO 92/13558	WIPO			
	8.	02/04/1993	WO 93/02093	WIPO			
	9.	03/16/1995	WO 95/07073	WIPO			
	10.	06/28/2001	WO 01/45669	WIPO			
	11.	11/01/2001	WO 01/80883	WIPO			
	12.	06/13/2002	WO 02/46208	WIPO			

RECEIVED

APR 24 2003

TECH CENTER 1600/2900

OTHER DOCUMENTS

(Including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
CR	13.	Alarcón-Segovia, D. et al. (2003). "LJP 394 for the Prevention of Renal Flare in Patients with Systemic Lupus Erythematosus," <i>Arthritis & Rheumatism</i> 48(2):442-454.
	14.	Craig, M. L. et al. (2000). "Clearance of Anti-Double-Stranded DNA Antibodies," <i>Arthritis & Rheumatism</i> 43(10):2265-2275.
	15.	Ferguson, P. J. et al. (1995). "Antigen-Based Heteropolymers," <i>Arthritis & Rheumatism</i> 38(2):190-200.

EXAMINER:

DATE CONSIDERED:

8/7/03



EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2-92)
pa-770929

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/08 (2-92)

Sheet 2 of 2

Form PTO-1449		Docket Number 252312007400	Application Number 09/724,822
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) 		Applicant Matthew D. LINNIK and Patricia A. McNEBLEY	
		Filing Date November 28, 2000	Group Art Unit 1636
		Mailing Date April 17, 2003	
16.	Taylor, R. P and Ferguson, P. J. (1995). "Immune Complexes (IC) Bound to Erythrocyte (E) CR1 via Anti-CR1 Mabs are Cleared Simultaneously with Loss of E CR1 in a Concerted Reaction in a Rhesus Monkey Model," Abstract 1000, <i>Arthritis and Rheumatism</i> 38(6):S320.		
17.	Taylor, R. P. and Ferguson, P. J. (1995). "Primate Erythrocyte (E) Complement Receptor (CR1) as an Anchor Site for Bispecific-Based Therapies to Clear Pathogens or Autoantibodies Safely from the Circulation," <i>Journal of Hematotherapy</i> 4:357-362.		
18.	Wiseman, A. (October 22, 2002). "La Jolla Pharmaceutical to Complete Enrollment of Phase III Lupus Clinical Trial." Press Release, two pages total.		
19.	Wiseman, A. (February 18, 2003). "La Jolla Pharmaceutical Announces Results of Phase III Trial of Riquent™." Press Release, six pages total.		
<div style="text-align: right;">RECEIVED APR 23 2003 GROUP 1/00</div>			
EXAMINER: 		DATE CONSIDERED: 8/7/03	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

PTO/SB/ 08 (2-92)

pa-770929

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/08 (2-92)
Sheet 1 of 2

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312807480	Application Number 09/724,822
	Applicant Matthew D. LINNIK and Patricia A. McNEELY	
	Filing Date November 28, 2000	Group Art Unit 1636
	Mailing Date July 10, 2003	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
CQ	1.	08/02/2001	2001/0010808	Yagi et al.			
	2.	08/01/2002	2002/0103343	Taylor et al.			
	3.	12/12/2002	2002/0187156	Dintzis et al.			
	4.	04/24/2003	2003/0077273	Linnik et al.			
	5.	06/09/1998	60/088,656	Marquis et al.			
	6.	10/05/1998	60/103,088	Marquis et al.			
	7.	12/09/1998	60/111,641	Jones			
	8.	06/08/1999	60/138,260	Jones et al.			
	9.	06/08/1999	09/328,199	Marquis et al.			
	10.	06/08/2000	09/590,592	Jones et al.			
	11.	06/07/2001	09/877,387	Jones			
	12.	02/23/1999	5,874,552	Jones et al.			
	13.	01/22/2002	6,340,460	Dintzis			
✓	14.	04/23/2002	6,375,951	Dintzis			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
CQ	15.	07/25/1991	WO 91/10426	WIPO			
	16.	06/14/2001	WO 01/41813	WIPO			
	17.	12/13/2001	WO 01/93914	WIPO			
✓	18.	11/21/2002	WO 02/092011	WIPO			

OTHER DOCUMENTS (including author, title, Date, Pertinent Pages, Etc.)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2-92)
pa-796669

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/08 (2-92)

Sheet 2 of 2

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

JUL 18 2003

(Use several sheets if necessary)

Docket Number 252312007400

Application Number 09/724,822

Applicant

Matthew D. LINNIK and Patricia A. McNEELY

Filing Date November 28, 2000

Group Art Unit 1636

Mailing Date July 10, 2003

Ref. No.	Initials	
19.	CR	Alarcon-Segovia, D. et al. (2000). SLI Trial Shows Fewer Renal Flares in LJP 394-Treated Patients with High-Affinity Antibodies to LJP 394:90-05 Trial Results," <i>Arth. Rheumat.</i> 43(9 supplement):S272 (abstract 1231).
20.		Furie, R.A. et al. (2001). "Treatment of Systemic Lupus Erythematosus with LJP 394," <i>J. Rheumatol.</i> 28:257-265.
21.		Henderson, A.L. et al. (2002). "Concerted Clearance of Immune Complexes Bound to the Human Erythrocyte Complement Receptor: Development of a Heterologous Mouse Model," <i>J Immunol Methods.</i> 270(2):183-97.
22.		Lindorfer, M.A. et al. (2001). "A Bispecific dsDNA-mono-clonal Antibody Construct for Clearance of Anti-dsDNA IgG in Systemic Lupus Erythematosus," <i>J. Immunol. Methods</i> 248(1-2):125-138.
23.		Linnik, M.D. and Bagin, R.G. (2000). "Effect of LJP 394 on Patients with Greatest Impairment of Renal Function at Baseline in the 90-05 Trial," <i>Arth. Rheumat.</i> 43(9 supplement):S241 (abstract 1046).
24.		Linnik, M.D. et al. (2000). "Affinity of Antibodies for LJP 394 Influences Pharmacodynamic Response to LJP 394 in SLB Patients with Positive dsDNA Antibody Titers," <i>Arth. Rheumat.</i> 43(9 supplement):S241 (abstract 1045).
25.		Pistiner, M. et al. (1991). "Lupus Erythematosus in the 1980s: A Survey of 570 Patients," <i>Semin. Arthritis Rehum.</i> 21(1):55-64.
26.		Strand, V. (2001). "Monoclonal Antibodies and Other Biologic Therapies," <i>Lupus</i> 10:216-221.
27.		Wallace, D.J. (2001). "Clinical and Pharmacological Experience with LJP-394," <i>Expert Opinion of Investigational Drugs</i> 10(1):111-117.

RECEIVED

JUL 17 2003

TECH CENTER 1600/2900

EXAMINER:

DATE CONSIDERED:

4/30/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2-92)

pa- 796669

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/08 (2-92)

Sheet 1 of 5

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION FEB 13 2004 (Use several sheets if necessary) PATENT & TRADEMARK OFFICE	Docket Number 2523 L2007400	Application Number 09/724,822
	Applicant Matthew D. LINNIK et al.	
	Filing Date November 28, 2000	Group Art Unit 1636
	Mailing Date February 13, 2004	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
CQ	1.	08/02/2001	2001/0010818	Engle et al.			
	2.	06/19/2003	2003/0114405	Linnik et al.			
	3.	12/07/1993	5,268,454	Barstad et al.			
	4.	10/06/1998	5,817,752	Yu			
	5.	01/05/1999	5,856,464	Livingston			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
CA	6.	12/19/1996	WO 96/40708	WIPO			
V	7.	12/11/1997	WO 97/46248	WIPO			

OTHER DOCUMENTS (Including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	
CQ	8.	Alarcon-Segovia, D. et al. (2001). "SLE Trial Shows Fewer Renal Flares in LJP 394-Treated Patients with High-Affinity Antibodies to LJP 394:90-05 Trial Results," located at < http://www.ljpc.com/abstracts/abstract_2001_02.html > visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 1 page.
	9.	Alarcon-Segovia, D. et al. (2003). "LJP 394 for the Prevention of Renal Flare in Patients with Systemic Lupus Erythematosus: Results from a Randomized, Double-Blind, Placebo-Controlled Study," located at < http://www.ljpc.com/abstracts/abstract_2003_01.html > visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 2 pages.
	10.	Alarcon-Segovia, D. et al. (2003). "SLE Trial Shows Fewer Renal Flares in LJP 394-Treated Patients with High-Affinity Antibodies to LJP 394:90-05 Trial Results," located at < http://www.ljpc.com/abstracts/abstract_2000_sle_trial.html > visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 2 pages.
	11.	Alarcon-Segovia, D. et al. "SLE Trial Shows Fewer Renal Flares in LJP-394 Treated Patients with High-Affinity Antibodies to LJP-394: 90-05. Trial Results," <i>Lupus</i> 10 (Supplement 1):pS272: 1231.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

pa- 819949PTO/SB/ 08 (2-92)


Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/08 (2-92)

Sheet 2 of 5

Form PTO-1449 INFORMATION DISCLOSURE CITATION ON AN APPLICATION FEB 13 2004 (Use several sheets if necessary)		Docket Number 252312007400	Application Number 09/724,822
		Applicant Matthew D. LINNIK et al.	
		Filing Date November 28, 2000	Group Art Unit 1636
		Mailing Date February 13, 2004	

C-Q	12.	Cardiel, M. (2003). "Randomized, Placebo Controlled, Double-Blind Phase III Clinical Trial for the Evaluation of LJP 394 (Abetimus Sodium) in the Treatment of Patients with SLE who are at Risk for Renal Flare," located at < http://www.ljpc.com/abstracts/abstract_2003_02.html > visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 2 pages.
	13.	Cardiel, M.H. et al. (2003). "Clinical Efficacy Results from a RCT of LJP 394 in SLE Patients with History of Renal Disease," <i>Arthritis and Rheumatism</i> 48(9):582-583.
	14.	Cardiel, M.H. et al. (2003). "Clinical Efficacy Results from a RCT of LJP 394 in SLE Patients with History of Renal Disease," located at < http://www.ljpc.com/abstracts/abstract_2003_07.html > visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 2 pages.
	15.	Furie, R.A. et al. (2000). "Treatment of Systemic Lupus Erythematosus with LJP 394," located at < http://www.ljpc.com/abstracts/abstract_2001_16.html > visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 1 page.
	16.	Iverson et al. (1998) "A Chemically Defined, Toleragen-Based Approach for Targeting Anti- β_2 -glycoprotein I Antibodies" <i>Lupus</i> 7 (Suppl 2): S166-S169.
	17.	Iverson et al. (1998) "Anti- β_2 glycoprotein I (B2GPI) Autoantibodies Recognize an Epitope on the First Domain of B2GPI" <i>Proc Natl Acad Sci USA</i> 95:15542-15546.
	18.	Jones et al. (1998) "Synthesis of a Cyclic-Thioether Peptide which Binds Anti-Cardiolipin Antibodies" <i>Tetrahedron Letters</i> 39:6107-6110.
	19.	Jones, D. (1991). "Case Study: Lupus Nephritis," <i>American Nephrology Nurses' Association</i> 18(3):327-329.
	20.	Jones, D. (1994). "A New Oligonucleotide Conjugate for Suppression of Anti-Double Stranded DNA Antibodies," <i>Abstracts of Papers American Chemical Society</i> 207(1-2):pBIOT 113.
	21.	Kandiah et al. (1998) "Current Insights into the "Antiphospholipid" Syndrome: Clinical, Immunological, and Molecular Aspects" <i>Advances in Immunology</i> 70:507-563.
	22.	La Jolla Pharmaceutical Co. Press Release. (March 31, 2003). "Results from Two Riquent TM Trials Show Lupus Patients with Sustained Reductions in Antibodies to dsDNA Have Fewer Renal Flares," San Diego, CA. 4 pages.
	23.	Linnik, M.D. et al. (2000). "Affinity of Antibodies for LJP 394 Influences Pharmacodynamic Response to LJP 394 in SLE Patients with Positive dsDNA Antibody Titers," <i>Arthritis and Rheumatism</i> 43(9):1045.
	24.	Linnik, M.D. et al. (2000). "Affinity of Antibodies for LJP 394 Influences Pharmacodynamic Response to LJP 394 in SLE Patients with Positive dsDNA Antibody Titers," located at < http://www.ljpc.com/abstracts/abstract_2000_affinity.html > visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 2 pages.
	25.	Linnik, M.D. et al. (2000). "Effect of LJP 394 on Patients with Greatest Impairment of Renal Function at Baseline in the 90-05 Trial," <i>Arthritis and Rheumatism</i> 43(9):1046.
↓	26.	Linnik, M.D. et al. (2000). "Effect of LJP 394 on Patients with Greatest Impairment of Renal Function at Baseline in the 90-05 Trial," located at < http://www.ljpc.com/abstracts/abstract_2000_effect.html > visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 1 page.

EXAMINER: 	DATE CONSIDERED: 4/3/04
---	----------------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

pa- 819949PTO/SB/ 08 (2-92) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/08 (2-92)

Sheet 3 of 5

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 252312007400

Application Number 09/724,822

Applicant

Matthew D. LINNIK et al.

Filing Date November 28, 2000

Group Art Unit 1636

Mailing Date February 13, 2004

27. Linnik, M.D. et al. (2000). "Reduction in Anti-dsDNA Antibodies by LJP 394 in Lupus Patients is Influenced by Affinity for the LJP 394 dsDNA Eptiope," located at <http://www.ljpc.com/abstracts/abstract_2000_reduction.html> visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 2 pages.
28. Linnik, M.D. et al. (2001). "Affinity of Antibodies for LJP 394 Influences Pharmacodynamic Response to LJP 394 in SLE Patients," located at <http://www.ljpc.com/abstracts/abstract_2001_04.html> visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 1 page.
29. Linnik, M.D. et al. (2001). "Affinity of Antibodies for LJP 394 Influences Pharmacodynamic Response to LJP 394 in SLE Patients," *Lupus* 10(Supplement 1):pS52:30.
30. Linnik, M.D. et al. (2001). "Effect of LJP 394 on SLE Patients with Impaired Renal Function," located at <http://www.ljpc.com/abstracts/abstract_2001_03.html> visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 1 page.
31. Linnik, M.D. et al. (2001). "Effect of LJP 394 on SLE Patients with Impaired Renal Function," *Lupus* 10(Supplement 1):pS17:19.
32. Linnik, M.D. et al. (2001). "Effect of LJP 394 or High Dose Corticosteroids and Cyclophosphamide on Anti-dsDNA Antibodies in SLE Patients," located at <http://www.ljpc.com/abstracts/abstract_2001_09.html> visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 2 pages.
33. Linnik, M.D. et al. (2001). "Effect of LJP or High Dose Corticosteroids and Cyclophosphamide on Anti-dsDNA Antibodies in SLE Patients," *Arthritis and Rheumatism* 44(9):S282:1378.
34. Linnik, M.D. et al. (2002). "Workshop Report on Some New Ideas About the Treatment of Systemic Lupus Erythematosus" *Lupus* 11:793-796.
35. Linnik, M.D. et al. (2002). "Effect of LJP 394 or High Dose Corticosteroids and Cyclophosphamide on Anti-dsDNA Antibodies in SLE Patients," located at <http://www.ljpc.com/abstracts/abstract_2002_05.html> visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 2 pages.
36. Linnik, M.D. et al. (2002). "Effect of LJP 394, High Dose Corticosteroids and Cyclophosphamide (HDCC) on Anti-dsDNA Antibodies in SLE Patients," located at <http://www.ljpc.com/abstracts/abstract_2002_02.html> visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 1 page.
37. Linnik, M.D. et al. (2002). "Reduction in Antibodies to dsDNA Using LJP in Dose Ranging Trial in Lupus Patients," located at <http://www.ljpc.com/abstracts/abstract_2002_01.html> visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 1 page.
38. Linnik, M.D. et al. (2002). "Workshop Report on Some New Ideas about the Treatment of Systemic Lupus Erythematosus," located at <http://www.ljpc.com/abstracts/abstract_2002_10.html> visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 1 page.
39. Linnik, M.D. et al. (2003). "Reductions in Anti-DSDNA Antibodies and Reduced Risk of SLE Renal Flare and Major SLE Flare," located at <http://www.ljpc.com/abstracts/abstract_2003_09.html> visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 2 pages.

EXAMINER:

DATE CONSIDERED:

4/30/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

pa- 819949PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/08 (2-92)

Sheet 4 of 5

Form PTO-1449		Docket Number 252312007400	Application Number 09/724,822
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Matthew D. LINNIK et al.	
		Filing Date November 28, 2000	Group Art Unit 1636
		Mailing Date February 13, 2004	
40.	Linnik, M.D. et al. (2003). "SLE Patients with Sustained Reductions in Anti-dsDNA Antibodies Have a Reduced Risk of Renal Flare and Major SLE Flare," located at < http://www.ljpc.com/abstracts/abstract_2003_05.html > visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 2 pages.		
41.	McNeeley, P.A. et al. (2000). "Lupus Patient Pharmacodynamic Response to LJP 394 is Influenced by Pre-Treatment Antibody Affinity for LJP 394," located at < http://www.ljpc.com/abstracts/abstract_2000_pharmaco_response.html > visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 2 pages.		
42.	McNeeley, P.A. et al. (2001). "Pre-Treatment Affinity for LJP 394 Influences Pharmacodynamic Response in Lupus Patients," located at < http://www.ljpc.com/abstracts/abstract_2001_13.html > visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 1 page.		
43.	Morimoto, C. et al. (1982). "Correlation Between Clinical Activity of Systemic Lupus Erythematosus and the Amounts of DNA in DNA/Anti-DNA Antibody Immune Complexes," <i>J. Immunol.</i> 139(5):1960-1965.		
44.	Morimoto, C. et al. (1987). "A Defect of Immunoregulatory T Cell Subsets in Systemic Lupus Erythematosus Patients Demonstrated with Anti-2H4 Antibody," <i>J Clin Invest.</i> 79(3):762-768.		
45.	Saffran, D.C. et al. (2002). "Treatment of Antibody-Mediated SLE-Like Disease in Male BXSB Mice with a B-Cell Toleragen Specific for Anti-dsDNA Antibodies," located at < http://www.ljpc.com/abstracts/abstract_2002_04.html > visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 1 page.		
46.	Sem, D.S. et al. (1998). "Structural Characterization and Optimization of Anti-body Selected Phage Library Mimotopes of an Antigen Associated with Autoimmune Recurrent Thrombosis," <i>Biochemistry</i> 37(46):16069-16091.		
47.	Tumlin, J.A. et al. (2001). "The B-Cell Toleragen LJP-394 Reduces Renal Flares in Patients with Lupus Nephritis: A Prospective Double-Blinded, Placebo Controlled Trial," located at < http://www.ljpc.com/abstracts/abstract_2001_08.html > visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 2 pages.		
48.	Tumlin, J.A. et al. (2001). "The B-Cell Toleragen LJP-394 Reduces Renal Flares in Patients with Lupus Nephritis: A Prospective, Double-Blinded, Placebo Controlled Trial," <i>Journal of the American Society of Nephrology</i> 12:p253A.		
49.	Tumlin, J.A. et al. (2003). "Efficacy Results from a RCT of LJP 394 in SLE Patients with History of Renal Disease," located at < http://www.ljpc.com/abstracts/abstract_2003_10.html > visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 2 pages.		
50.	Tumlin, J.A. et al. (2003). "Renal Flare in SLE Patients with Impaired Renal Function in a RCT of LJP 394," located at < http://www.ljpc.com/abstracts/abstract_2003_12.html > visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 2 pages.		
51.	Wallace, D.J. et al. (2003). "Safety Results from a Randomized Controlled Trial (RCT) of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients with a History of Renal Disease," located at < http://www.ljpc.com/abstracts/abstract_2003_06.html > visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 2 pages.		
EXAMINER:		DATE CONSIDERED: 4/30/04	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
pa- 819949PTO/SB/ 08 (2-92)		Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE	

PTO/SB/08 (2-92)

Sheet 5 of 5

Form PTO-1449

Docket Number 252312007400

Application Number 09/724,822

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Matthew D. LINNIK et al.

Filing Date November 28, 2000

Group Art Unit 1636

Mailing Date February 13, 2004

FEB 13 2004

32.

Wallace, D.J. et al. (2003). "Safety Results from a RCT of LJP 394 in SLE Patients with a History of Renal Disease," located at <http://www.ljpc.com/abstracts/abstract_2003_11.html> visited on December 8, 2003. La Jolla Pharmaceutical Co. Abstracts. 2 pages.

EXAMINER: 

DATE CONSIDERED:

4/30/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

pa- 819949PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE